WEP Clinical is committed to supporting companies in the pharmaceutical industry to help make much-needed medicines available to patients, physicians, hospitals and research and development centers around the world. The case studies below help demonstrate our capabilities and expertise and highlight the best-in-class service we provide.

Using expanded access to treat patients that do not qualify for the clinical trial

USING EXPANDED ACCESS TO PROVIDE CONTINUATION OF TREATMENT POST CLINICAL TRIALS

USING EXPANDED ACCESS AS AN ALTERNATIVE TO AN OPEN LABEL EXTENSION (OLEX) STUDY

USING EXPANDED ACCESS To supply a large global patient population

USING EXPANDED ACCESS TO TREAT VARIOUS PATIENT GROUPS

navigating fda approval while providing treatment access through an EXPANDED ACCESS program

NAVIGATING THROUGH sponsor aquisitions and changeovers while providing an EXPANDED ACCESS program

adjusting to new brexit landscape while providing an EXPANDED ACCESS program

PROVIDING A NAMED PATIENT PROGRAM WITH A VARIed aND AFFORDABLE PRICING PLAN

Overcoming difficulties shipping a Named Patient Program product to Belarus

Setting Up a 24/7/365 Emergency Medicines Supply Service for a Named Patient Program with Tight Timelines

Helping a Company Introduce and Commercialise its Health Canada Approved Product in the European Market

Providing High-Cost Products to Patients ex-US/EU through a Named Patient Program

Working with an Advocacy Group to Help a Patient in Barbados Access a Life-Saving Drug from the US

Not-for-Profit Supply of a Treatment to a Rare Disease Patient Population in the USA and Other ex-EU Countries

Making Life-Saving Treatment Available to Patients on an Unlicensed Basis in Neglected or Overlooked Countries

Emergency medicine supply service to a patient in Iceland

NEED MORE INFORMATION?